Overview

• Two randomized trials found a weekly 7.2 mg dose led to larger average weight loss than the approved 2.4 mg dose or placebo in adults with obesity.
• Participants without diabetes lost nearly 19% of body weight on 7.2 mg versus about 16% on 2.4 mg and 4% with placebo.
• Among those with type 2 diabetes, average loss was roughly 13% on 7.2 mg compared with 10% on 2.4 mg and 4% on placebo.
• Gastrointestinal effects such as nausea and diarrhea were most common and generally manageable, with no increase in serious adverse events or severe hypoglycemia.
• Nearly half on the higher dose lost at least 20% of body weight, one-third reached 25% or more, and the sponsor Novo Nordisk disclosed funding of the trials published Sept. 14 in The Lancet Diabetes & Endocrinology.